Garnet Biotherapeutics Reels In Venture Capital Funding
Friday, January 30, 2009 5:38:00 AM PDT | VentureDeal Staff
Malvern, Pennsylvania -- Biotechnology company Garnet Biotherapeutics has secured $10.4 million in new venture capital investment.
Garnet has developed technology to expand bone marrow derived cells that may help patients accelerate healing and reduce scarring from injuries.
SCP Partners led the round, which included Safeguard Scientifics and Alliance Technology Ventures. The company said it would use the funding for its Phase II clinical trials.
Email Page | Print Page